Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)currently has a Zacks Rank #2 (Buy) while its Earnings ESP is negative. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) stock advanced 19.55% and finished the last session at $8.99. The EPS of the stock remained -1.46. Company’s market capitalization is $1.67 billion.
PTC Therapeutics, Inc. (NASDAQ:PTCT) announces CHMP of the EMA has adopted a negative opinion on the co’s MAA for conditional approval of ataluren for the treatment of nonsense mutation Duchenne muscular dystrophy; co appoints Robert J. Spiegel to Chi. PTC Therapeutics, Inc. (NASDAQ:PTCT) stock opened at $21.85 in last trading session, and closed at $26.90, trading in the range of $21.75 – $27.67. The stock showed a positive weekly performance of 1.32%.
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, announced it has initiated a Phase 2 clinical trial to determine preliminary efficacy and safety of aldoxorubicin for HIV-infected patients with Kaposi’s sarcoma (KS). CytRx Corporation (NASDAQ:CYTR) shares closed at $7.27 on last trade day, by gaining 2.83%. Stock 52 week range is $1.83 – $8.24. Company’s market capitalization is $305.16 billion.